Approval to expand the product matrix to include the 2.25 mm xience v everolimus eluting coronary stem system. this device size will be marketed under the trade name xience  nano everolimus eluting coronary stem system and will also be distributed as the promus everolimus eluting coronary stent system.  The addition of the 2.25 mm xience nano everolimus eluting coronary stent system will expand the originally approved indications to include treatment of coronary artery lesions with reference vessel diameters >2.25 mm to <2.50 mm. therefore, the xience v everolimus eluting coronary stent system is now indicated for improving coronary luminal diameter inpatients with symptomatic heart disease due to de novo native coronary artery lesions (length < 28 mm) with reference vessel diameters of 2.25 mm to 4.25 mm.